Hot Topics: Institutions, Centers, Funding
This post can also be found as the November 2018 editorial in the American Journal of Bioethics.
by Alonzo L.…Full Article
by Craig Klugman, Ph.D.
Like most members of the American Society for Bioethics & Humanities (ASBH), I received an email last week geared toward enticing me to sign up to take the new Healthcare Ethics Consultant accreditation exam.…Full Article
by Craig Klugman, Ph.D.
Last week, I was interviewed by an academic news serviceabout antimicrobial resistance (AMR) after a study reported that giving antibiotics to children in selected African towns led to a decreased mortality rate. …Full Article
Chicago Med (Season 3; Episode 4)
Confidentiality: A husband comes into the ER with his wife who is experiencing Braxton Hicks contractions.…Full Article
by Craig Klugman, Ph.D.
Senator and former Presidential candidate Rand Paul introduced S. 1973, a bill that would change how scientific grant proposals are reviewed.…Full Article
Health Research Priority Setting: The Duties of Individual Funders
Aligning Research Priorities to Improve Equity: A Challenge for Health Funders
Growing an ethics consultation service: A longitudinal study examining two decades of practice
Improving third-year medical students' competency in clinical moral reasoning: Two interventions
There’s a new war raging in health care, with hundreds of millions of dollars at stake and thousands of lives in the balance. The battle, pitting drug companies against doctors and patient advocates, is being fought over the unlikeliest of substances: human excrement.
The clash is over the future of fecal microbiota transplants, or F.M.T., a revolutionary treatment that has proved remarkably effective in treating Clostridioides difficile, a debilitating bacterial infection that strikes 500,000 Americans a year and kills 30,000.
The therapy transfers fecal matter from healthy donors into the bowels of ailing patients, restoring the beneficial works of the community of gut microbes that have been decimated by antibiotics. Scientists see potential for using these organisms to treat diseasesfrom diabetes to cancer.
At the heart of the controversy is a question of classification: Are the fecal microbiota that cure C. diff a drug, or are they more akin to organs, tissues and blood products that are transferred from the healthy to treat the sick? The answer will determine how the Food and Drug Administration regulates the procedure, how much it costs and who gets to profit.Full Article
A near-drowning had left the woman in a persistent vegetative state for nearly a decade. So when she went into labor a few days after Christmas, her caretakers were flummoxed.
On Dec. 29, with help from one of the facility’s nurses, the patient gave birth to a healthy baby boy, KPHO reported. The birth — and the sexual assault of a vulnerable individual that must have preceded it — has cast a harsh glare on conditions at a nonprofit organization that bills itself as a leading provider of health care for Phoenix’s medically fragile.Full Article
Six months after halting a study of moderate drinking that was underwritten by donations from the alcohol industry, the National Institutes of Health outlined a series of steps to prevent similar conflicts of interest and to safeguard the integrity of its research and its reputation.
In a report issued on Thursday, N.I.H. officials said its 27 institutes must evaluate all current research projects that receive private donor support for conflicts of interest of the kind that compromised the alcohol trial. The institute directors are to report their findings to Dr. Francis Collins, director of N.I.H., early next year.Full Article
It sounds like science fiction: A research program funded by the U.S. government plans to create virus-carrying insects that, released in vast numbers, could help crops fight threats such as pests, drought, or pollution. “Insect Allies,” as the $45 million, 4-year program is called, was launched in 2016 with little fanfare. But in a policy forum in this week’s issue of Science, five European researchers paint a far bleaker scenario.Full Article
Last month, NSF’s biology directorate announced that researchers could submit only one proposal a year in which they are listed as a principal investigator (PI) or co-PI. The cap applies only to the directorate’s three core tracks and excludes several other NSF programs from which many biologists receive support… But 70 scientists have signed onto a letter asking the agency to reconsider the new policy, which they also complain was adopted without any community input.Full Article
Finland’s national research funder has signed up to Plan S — a push by a group of European organizations to make a radical change to the way that research results are published. The Academy of Finland, which announced its move on 24 September, is the first organization to sign up since Plan S was launched by 11 funders earlier this month. The now 12-strong coalition demands that, from 2020, papers resulting from the research they fund are immediately free to read on publication.Full Article
Congress has approved a $2 billion raise, to $39.1 billion, for the National Institutes of Health (NIH) in a 2019 spending bill approved by House of Representatives and Senate negotiators last night. As expected, the 5% boost matches the Senate’s proposed spending level and surpasses a $1.25 billion increase in a draft bill passed by the House.Full Article
The fall from grace last week of Dr. José Baselga, the former chief scientific officer of Memorial Sloan Kettering Cancer Center, illuminated a longstanding problem of modern medicine: Potentially corrupting payments by drug and medical device makers to influential people at research hospitals are far more common than either side publicly acknowledges.
The NIH envisions using the RAC as an advisory board on to- day’s emerging biotechnologies, such as gene editing, synthetic bi- ology, and neurotechnology, while harnessing the attributes that have long ensured its transparency. We at the NIH and the FDA look for- ward to working together with all our stakeholders to implement thesechanges.Wesharecommon goals: advancing science and hu- man health and accelerating the availability of safe and effective gene therapy, along with the many promising new products that fu- ture biotechnologies may bring.